---
canonical_name: Urolithin A
alternate_names: UA, Mitopure, 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one, urolithin-A
canonical_topic: Urolithin A for Health & Longevity
short_topic_lc: urolithin_a
creation_date: 2026-0701-0004
creator_ai_fullname: Opus 4.8
---

# Urolithin A for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 07/01/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** UA, Mitopure, 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one, urolithin-A


## Motivation

<!-- This motivation section was written after the rest of the document was completed, so it reflects the full scope of the topic. -->

Urolithin A is a compound the body does not make on its own. Instead, certain gut bacteria produce it after a person eats foods rich in plant compounds called ellagitannins — found in pomegranates, walnuts, and berries. Interest centers on its apparent ability to trigger the cellular "cleanup" of worn-out mitochondria, the tiny structures that power our cells. Because this cleanup slows with age, Urolithin A has drawn attention as a possible way to support muscle and cellular health as people grow older.

A practical complication drives much of the interest: only an estimated third to half of people carry the gut bacteria needed to make meaningful amounts of Urolithin A from food. This gap spurred the development of a supplement form, allowing anyone to reach the levels seen in research regardless of their gut bacteria. Early human trials reported gains in muscle endurance and strength in middle-aged and older adults.

This review examines the evidence for and against Urolithin A as a tool for health and longevity. It looks at what the compound does in the body, the benefits and risks supported by human trials, how it is used, and where the science remains unsettled.


**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-quality, accessible overviews of Urolithin A from trusted experts and publications.

<!-- A real-time search was performed across web search and the platforms of prioritized experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension). Relevant content was found from Rhonda Patrick (FoundMyFitness) and the foundational narrative review by the discovering research group. No dedicated Urolithin A article was found on Peter Attia, Chris Kresser, or Life Extension sites at the time of writing. -->

* [Urolithin A](https://www.foundmyfitness.com/topics/urolithin-a) - Rhonda Patrick

  A curated topic hub collecting Dr. Patrick's articles, study summaries, and Q&A clips on Urolithin A, with a focus on mitophagy, muscle strength, and the gut-microbiome origins of the compound.

* [Impact of the Natural Compound Urolithin A on Health, Disease, and Aging](https://pubmed.ncbi.nlm.nih.gov/34030963/) - D'Amico et al., 2021

  A comprehensive narrative review covering Urolithin A's discovery, mechanism, and early clinical data; valuable for understanding the biology, though note its authors are affiliated with the supplement's developer.

* [Pharmacological Effects of Urolithin A and Its Role in Muscle Health and Performance: Current Knowledge and Prospects](https://pubmed.ncbi.nlm.nih.gov/37892516/) - Zhao et al., 2023

  A focused narrative review of the muscle and exercise-performance literature, useful for readers wanting a deeper look at the mechanistic basis of the strength and endurance findings.

* [Urolithin A Is a Dietary Microbiota-Derived Human Aryl Hydrocarbon Receptor Antagonist](https://pubmed.ncbi.nlm.nih.gov/30501068/) - Muku et al., 2018

  A primary research article identifying an additional molecular target of Urolithin A beyond mitophagy, helping explain its anti-inflammatory effects.

* [Effect of the Mitophagy Inducer Urolithin A on Age-Related Immune Decline](https://pubmed.ncbi.nlm.nih.gov/41174221/) - Denk et al., 2025

  A recent placebo-controlled trial extending the evidence base from muscle into immune function, reporting shifts toward a more youthful immune-cell profile in midlife adults.

<!-- Only content discussing Urolithin A by name in depth was included. No relevant dedicated content was located on peterattiamd.com, chriskresser.com, or lifeextension.com despite both web and on-site searches; this is noted here for transparency. -->

*Note: Despite both web and on-site searches, no relevant dedicated Urolithin A content was found from Peter Attia, Chris Kresser, or Life Extension, so no items from these priority sources are listed above.*


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool for "Urolithin A". A dedicated article was found at grokipedia.com/page/Urolithin_A. -->

* [Urolithin A](https://grokipedia.com/page/Urolithin_A)

  Grokipedia hosts a dedicated entry covering Urolithin A's chemistry, microbial production from ellagitannins, mechanism of action, and the clinical trial landscape.


## Examine

<!-- examine.com was searched directly using the browser tool for "Urolithin A". A dedicated supplement page was found. -->

* [Urolithin A](https://examine.com/supplements/urolithin-a/)

  Examine provides an evidence-graded summary of Urolithin A's effects on muscle and mitochondrial outcomes, with a critical appraisal of the strength and quality of the human trials.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool for "Urolithin A". A dedicated answer article on Urolithin A for muscle health was found. -->

* [Urolithin A For Age-Related Muscle Decline?](https://www.consumerlab.com/answers/does-urolithin-a-reduce-age-related-muscle-decline/urolithin-a-for-muscle-health/)

  ConsumerLab reviews the evidence for Urolithin A in age-related muscle decline and discusses product considerations, including a note that the maker of the leading branded product agreed to modify some of its marketing claims.


## Systematic Reviews

This section summarizes the systematic reviews and meta-analyses of Urolithin A identified through a real-time PubMed search.

* [Targeting Aging With Urolithin A in Humans: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/39002645/) - Kuerec et al., 2024

  Pooling five human trials of 250 healthy individuals, this review found a dose-dependent anti-inflammatory effect and upregulation of mitochondrial genes, with improved muscle strength and endurance but no effect on maximal ATP (adenosine triphosphate, the cell's main energy currency) production, anthropometrics, or cardiovascular outcomes.

* [The Therapeutic Relevance of Urolithins, Intestinal Metabolites of Ellagitannin-Rich Food: A Systematic Review of In Vivo Studies](https://pubmed.ncbi.nlm.nih.gov/36079752/) - Tow et al., 2022

  A synthesis of 41 animal studies cataloguing neuroprotective, metabolic, cardiac, and musculoskeletal effects, and identifying the SIRT1 (a longevity-linked enzyme), AMPK (a cellular fuel gauge), and PI3K/AKT/mTOR (a growth- and nutrient-sensing pathway) signaling pathways as central to the autophagy and mitochondrial benefits.

* [Impact of Nutraceuticals and Dietary Supplements on Mitochondria Modifications in Healthy Aging: A Systematic Review of Randomized Controlled Trials](https://pubmed.ncbi.nlm.nih.gov/35920994/) - Lippi et al., 2022

  A broad review of supplements targeting mitochondria in aging that includes Urolithin A among the compounds with the most consistent randomized-trial support for measurable mitochondrial gene and biomarker changes.


## Mechanism of Action

Urolithin A is not consumed directly in the diet; it is a gut-bacterial metabolite. When ellagitannins from pomegranate, walnuts, or berries reach the colon, specific bacteria convert them — through the intermediate ellagic acid — into Urolithin A. The capacity to perform this conversion varies widely between individuals, which is why supplementing the finished compound bypasses an unreliable step.

The headline mechanism is the stimulation of **mitophagy** (the selective recycling of damaged mitochondria). Aged or dysfunctional mitochondria are tagged and engulfed for disposal, making room for fresh, efficient ones. By clearing defective mitochondria, Urolithin A is proposed to improve the overall quality and energy output of the mitochondrial pool in tissues with high energy demand, such as skeletal muscle. In animal and cellular work, this proceeds via conserved energy-sensing pathways including AMPK (AMP-activated protein kinase, a cellular fuel gauge) and is accompanied by modest mitochondrial biogenesis (the growth of new mitochondria).

A second mechanism is anti-inflammatory. Urolithin A acts as an antagonist of the aryl hydrocarbon receptor (AhR, a sensor that influences immune and inflammatory signaling) and reduces inflammatory signaling, consistent with the lowered C-reactive protein (CRP, a blood marker of body-wide inflammation) seen in human trials.

Competing interpretations exist. Skeptics note that while mitophagy markers and gene expression rise, several trials failed to show changes in the functional endpoint that mitophagy should most directly improve — maximal mitochondrial ATP production measured in living muscle — leaving open whether the biomarker shifts translate into meaningful bioenergetic change.

As an orally administered compound, Urolithin A is absorbed and rapidly conjugated in the gut and liver into glucuronide and sulfate forms, which dominate in the bloodstream. Plasma levels of these conjugates peak several hours after a dose, and the compound is not known to meaningfully inhibit or induce major cytochrome P450 (CYP) drug-metabolizing enzymes at typical intakes. It is cleared primarily through bile and urine.


## Historical Context & Evolution

Urolithins were first described decades ago as obscure end-products of polyphenol metabolism, of interest mainly to researchers studying how the gut handles pomegranate and walnut compounds. For years they were viewed as markers of polyphenol intake rather than bioactive agents in their own right.

The reframing came when a research group (later commercialized as Amazentis) reported in animal models that Urolithin A extended lifespan in roundworms and improved muscle function in aged rodents, attributing the effect to restored mitophagy. This shifted Urolithin A from a metabolic curiosity to a candidate longevity compound and motivated its development as a defined supplement so that intake no longer depended on an individual's gut bacteria.

The original preclinical findings — improved muscle endurance and mitochondrial markers in aged animals — have largely held up on replication, and subsequent human trials confirmed safety and reproduced some biomarker and strength signals. What remains debated is the size and clinical meaningfulness of the human benefit, and whether effects extend beyond muscle. The field has not declared the early enthusiasm either vindicated or overturned; instead, the evidence has matured from "promising in animals" to "modest but measurable in humans," with the most important functional questions still under active study.


## Expected Benefits

A dedicated search of clinical trials, systematic reviews, and expert sources was performed to assemble the benefit profile below, framed for proactive, health-focused adults.


### Medium 🟩 🟩

#### Improved Muscle Endurance

Across multiple placebo-controlled trials in middle-aged and older adults, Urolithin A increased the number of muscle contractions to fatigue and improved measures of local muscular endurance. The proposed mechanism is improved mitochondrial quality in working muscle. Evidence comes from at least two randomized controlled trials (RCTs) and is reinforced by a systematic review pooling five human studies; effects are consistent in direction though modest in size, and most participants were sedentary to moderately active rather than athletes.

**Magnitude:** Endurance (contractions to fatigue) improved meaningfully versus placebo in hand and leg muscles after 2–4 months; absolute gains varied by muscle and population.

#### Improved Muscle Strength

In a 4-month trial in middle-aged adults, Urolithin A produced roughly a 12% improvement in muscle strength versus placebo. The mechanism is again attributed to enhanced mitophagy and mitochondrial efficiency in skeletal muscle. The signal is supported by a randomized controlled trial and echoed in the pooled systematic review, though the strength endpoint was a secondary outcome in the key trial and warrants confirmation in larger studies.

**Magnitude:** ~12% improvement in lower-body/leg muscle strength versus placebo over 4 months in middle-aged adults.

#### Reduced Markers of Inflammation

Urolithin A lowered C-reactive protein (CRP) and other inflammatory and metabolic biomarkers (such as certain acylcarnitines and ceramides) in controlled trials, consistent with its anti-inflammatory aryl hydrocarbon receptor activity. This is relevant to longevity given the role of chronic low-grade inflammation in age-related decline. Evidence derives from biomarker endpoints in two RCTs and a systematic review reporting a dose-dependent anti-inflammatory effect.

**Magnitude:** Statistically significant reductions in plasma CRP and acylcarnitines versus placebo; absolute changes were small and within normal ranges.


### Low 🟩

#### Activation of Mitophagy and Mitochondrial Gene Expression

Human trials show that Urolithin A raises blood and skeletal-muscle markers of mitophagy and increases expression of mitochondrial and fatty-acid-oxidation genes. This is the most direct evidence that the compound engages its proposed target in people. However, these are surrogate molecular endpoints rather than clinical outcomes, and the systematic review notes that maximal ATP production and mitochondrial biogenesis measures did not consistently improve.

**Magnitude:** Significant upregulation of mitophagy and mitochondrial gene/protein markers in plasma and muscle biopsies; no consistent change in maximal muscle ATP synthesis.

#### Improved Aerobic Performance (VO₂ and Walking Distance) ⚠️ Conflicted

Some trials reported clinically meaningful improvements in peak oxygen consumption (VO₂, a measure of aerobic capacity) and 6-minute walk distance, while the primary aerobic endpoint (peak power output) was not significantly improved in the middle-aged trial, and the older-adult trial found no significant difference versus placebo on its co-primary walk-distance and ATP endpoints. The conflicting results likely reflect differences in age, baseline fitness, dose, and which endpoint was designated primary versus secondary.

**Magnitude:** Mixed — some trials showed improvements in VO₂ and 6-minute walk distance versus placebo; key primary aerobic endpoints were not met in others.

#### Support for Immune Cell Health

A 2025 placebo-controlled trial reported that Urolithin A shifted immune-cell profiles toward a more youthful pattern and improved mitochondrial fitness in immune cells of midlife adults. The proposed mechanism is mitophagy-driven improvement in T-cell metabolism. As a single, recent trial with intermediate biomarker endpoints, the finding is promising but not yet replicated.

**Magnitude:** Favorable shifts in circulating immune-cell subsets and immune-cell mitochondrial function versus placebo in one trial.


### Speculative 🟨

#### Joint and Cartilage Health

Preclinical and early-stage work suggests Urolithin A may reduce cartilage degeneration and pain in osteoarthritis models by improving mitochondrial health in joint tissue. The basis is animal studies and mechanistic reasoning; robust human efficacy data are lacking.

#### Cognitive and Neuroprotective Effects

Animal studies report neuroprotective and anti-inflammatory effects in models of cognitive decline, and human trials in cognition are now underway. At present the basis is mechanistic and preclinical only, with no completed human efficacy data.

#### Cardiovascular and Metabolic Benefits

Rodent data and small human signals hint at improved vascular function, lipid handling, and metabolic health, but human cardiovascular and anthropometric endpoints were not improved in completed trials. This remains speculative pending dedicated cardiovascular outcome studies.


## Benefit-Modifying Factors

* **Native Urolithin A producer status:** Individuals whose gut bacteria already convert ellagitannins efficiently ("urolithin producers") may derive less incremental benefit from supplementation than non-producers, who cannot generate meaningful amounts from diet alone. Producer status varies by individual microbiome composition.

* **Baseline mitochondrial and muscle status:** Benefits appear largest in those with age-related mitochondrial decline or lower baseline muscle function; well-trained athletes with already-efficient mitochondria have shown smaller or absent performance effects in trials.

* **Baseline inflammation:** Those with higher baseline inflammatory markers such as CRP may show more pronounced anti-inflammatory responses, since there is more room for improvement.

* **Age:** The strongest functional signals come from middle-aged and older adults; the target audience at the older end of the range, where mitophagy naturally declines, may be most likely to benefit.

* **Sex-based differences:** The pivotal older-adult trial was predominantly female (about three-quarters), limiting confidence in how strongly results generalize to men; dedicated sex-stratified efficacy analyses are largely lacking.

* **Pre-existing conditions:** Sedentary individuals and those with sarcopenia (age-related muscle loss) appear to gain more in endurance and strength than active, healthy individuals.


## Potential Risks & Side Effects

A dedicated search of clinical trial safety data, regulatory filings, and drug-reference sources was performed to assemble the risk profile below. Urolithin A has a notably clean short-term safety record across human trials.


### Low 🟥

#### Mild Gastrointestinal Symptoms

Across controlled trials, the most commonly reported adverse events were mild and gastrointestinal in nature — such as occasional digestive discomfort — with no significant difference in adverse-event rates between Urolithin A and placebo groups. The mechanism, where present, is likely local gut effects of an orally administered compound. Evidence comes from safety monitoring in multiple RCTs; events were graded mild to moderate and generally unrelated to treatment.

**Magnitude:** No statistically significant excess of adverse events versus placebo; reported events were mild and self-limiting.


### Speculative 🟨

#### Unknown Long-Term Safety

Human trials have generally lasted up to 4 months, so the safety of continuous use over years — the relevant horizon for a longevity intervention — has not been established. Because mitophagy and aryl hydrocarbon receptor signaling influence many tissues, prolonged manipulation could in theory have effects not captured by short trials. The basis for this concern is mechanistic and the absence of long-duration data, not any observed harm.

#### Theoretical Effects During Pregnancy and Lactation

Urolithin A has not been studied in pregnant or breastfeeding individuals, and its effects on a developing fetus are unknown. As with most supplements lacking such data, use in these populations cannot be supported on current evidence. This is a precautionary, data-absence concern rather than a documented risk.

#### Theoretical Interaction With Cancer Biology

Because Urolithin A modulates cell metabolism, mitophagy, and the aryl hydrocarbon receptor, and is being actively studied in cancer settings, its net effect in people with active malignancy is not yet defined and could plausibly differ from its effect in healthy adults. This remains speculative and is the subject of ongoing trials.


## Risk-Modifying Factors

* **Genetic and metabolic variation:** No specific polymorphisms are established as modifying Urolithin A risk. Individual differences in gut and liver conjugation (glucuronidation and sulfation) affect circulating levels but have not been linked to differential harm.

* **Baseline biomarkers:** No baseline lab value is known to predict adverse effects; the favorable safety profile appears broadly consistent across the populations studied.

* **Sex-based differences:** No sex-specific safety signal has emerged, though trial populations skewed female, limiting certainty in men.

* **Pre-existing conditions:** People with active cancer or those who are pregnant or breastfeeding fall outside the studied populations and represent the main groups for whom the risk-benefit balance is undefined.

* **Age:** No age-specific safety concern has been identified within the studied range of middle-aged through older adults; tolerability appeared similar across ages.


## Key Interactions & Contraindications

* **Prescription drug interactions:** No clinically significant prescription drug interactions are established. Urolithin A is not a known strong inhibitor or inducer of major cytochrome P450 (CYP) enzymes at typical doses, so direct pharmacokinetic interactions are not expected, though formal interaction studies are limited. **Severity: caution** — monitor when combined with narrow-therapeutic-index drugs (e.g., warfarin, digoxin, levothyroxine) given the limited data.

* **Over-the-counter medication interactions:** No specific over-the-counter (OTC) interactions are documented. Because Urolithin A and many OTC analgesics (e.g., acetaminophen, ibuprofen, aspirin) are processed by liver conjugation pathways, theoretical competition exists but has not been shown to be clinically relevant. **Severity: monitor.**

* **Supplement interactions:** No adverse supplement interactions are established. Urolithin A is frequently combined with creatine, protein, and other mitochondrial-support supplements (e.g., spermidine, Coenzyme Q10) without reported problems. **Severity: caution** — combinations are common but formally untested.

* **Additive effects:** Supplements and interventions that also target mitochondrial health or mitophagy (e.g., exercise, certain polyphenols, Coenzyme Q10) may have additive or complementary effects with Urolithin A, though this is based on mechanism rather than combination trials. **Severity: generally favorable**, not a safety concern.

* **Other interventions:** Urolithin A is being studied alongside immune checkpoint inhibitors in cancer; outside of supervised trials, combining it with active cancer therapy is not advised given undefined effects. **Severity: caution.**

* **Populations who should avoid it:** Pregnant or breastfeeding individuals (no safety data) and people with active cancer outside a clinical trial (undefined effect on tumor biology) are the populations for whom use is not supported. **Severity: avoid** pending data. There is no established threshold-based contraindication (e.g., by organ-function class) given the absence of relevant studies.


## Risk Mitigation Strategies

* **Start at a standard studied dose:** Use the doses validated in trials (typically 500–1000 mg daily) rather than escalating beyond studied amounts, since higher intakes have not been shown to add benefit and lack a long-term safety record. This mitigates the risk of unknown effects from supraphysiological intake.

* **Take with food to limit gastrointestinal discomfort:** Taking Urolithin A with a meal can reduce the mild digestive symptoms occasionally reported, addressing the most common (low-grade) side effect.

* **Periodic reassessment over long-term use:** Because trials extend only to about 4 months, those using Urolithin A continuously should reassess periodically (e.g., every 6–12 months) whether continued use is justified, mitigating the unknown-long-term-safety concern.

* **Avoid during pregnancy, breastfeeding, and active cancer (outside trials):** Excluding these populations directly addresses the speculative risks where the compound's effects are undefined.

* **Verify product identity and purity:** Choosing third-party-tested products mitigates the risk that a given supplement contains less Urolithin A than labeled or unwanted contaminants — a documented quality issue in this category.


## Therapeutic Protocol

* **Standard dose:** Leading practitioners and the pivotal trials use **500 mg or 1000 mg of Urolithin A once daily**. The 500 mg dose is the most common consumer protocol; the 1000 mg dose was used in the older-adult endurance trial. The compound was developed and popularized as the branded ingredient Mitopure by Amazentis/Timeline, whose researchers conducted much of the foundational work — a relevant commercial interest to note.

* **Conventional vs. dietary approach:** An alternative to supplementation is maximizing dietary ellagitannins (pomegranate, walnuts, berries), but this only produces meaningful Urolithin A in people whose gut bacteria can perform the conversion; supplementation is favored precisely because it removes that uncertainty. Neither approach is framed here as the default.

* **Best time of day:** No strong circadian dependence is established; the compound is typically taken once daily with a meal, and timing can be set for consistency rather than for a specific physiological window.

* **Half-life and dosing frequency:** Urolithin A and its conjugates have a plasma half-life on the order of hours, with conjugate levels sustained well after dosing; once-daily dosing is standard and split dosing has not been shown to be necessary.

* **Single vs. split dose:** A single daily dose is the studied and recommended approach; there is no evidence that splitting the dose improves outcomes.

* **Genetic and producer-status considerations:** No pharmacogenetic variant guides dosing. The most relevant individual factor is native producer status — non-producers stand to gain most from supplementation, since they cannot generate the compound from diet.

* **Sex-based considerations:** Trials have not established sex-specific dosing; the same doses were used across men and women, though women were over-represented in the key older-adult study.

* **Age-related considerations:** Older adults, in whom mitophagy declines, were studied at the higher 1000 mg dose; this dose is reasonable for those at the older end of the target range seeking the muscle and mitochondrial endpoints.

* **Baseline status and pre-existing conditions:** Those with lower baseline muscle function or higher inflammation may be the most appropriate candidates; people with active cancer or who are pregnant should not start outside of medical supervision.


## Discontinuation & Cycling

* **Lifelong vs. short-term:** Whether Urolithin A is best used continuously or in defined courses is unresolved; trials used continuous daily dosing for up to 4 months, and there is no evidence-based maximum duration. As a longevity supplement it is often used continuously, but long-term data are absent.

* **Withdrawal effects:** No withdrawal syndrome has been reported. Because the compound works by promoting an ongoing cellular cleanup process rather than altering a hormone or neurotransmitter system, stopping it is expected to simply return mitophagy signaling toward baseline.

* **Tapering:** No tapering protocol is needed or described; the compound can be stopped abruptly without known consequence.

* **Cycling:** No cycling regimen has been validated. Some users cycle on/off to limit cost and unknown long-term exposure, but there is no efficacy evidence that cycling preserves benefit better than continuous use.


## Sourcing and Quality

* **Defined, synthesized compound:** Most supplements use Urolithin A produced by chemical synthesis to a defined purity rather than extracted from food, which allows consistent dosing independent of pomegranate or walnut content.

* **Third-party testing:** Independent lab investigations have found that a substantial share of Urolithin A products on the market contained less than the labeled amount or failed quality checks, so third-party testing (for identity, potency, and contaminants) is especially important in this category.

* **Reputable products:** The branded ingredient Mitopure (Amazentis/Timeline) is the most extensively studied form and appears in several finished products; other brands using verified Urolithin A and providing certificates of analysis are reasonable alternatives. The branded product's commercial sponsorship of much of the research is a relevant consideration when weighing marketing claims.

* **Form and bioavailability:** The manufacturer has tested multiple formulations to optimize absorption; consumers should look for products that disclose the actual Urolithin A content (not just "pomegranate extract," which contains little to no preformed Urolithin A).


## Practical Considerations

* **Time to effect:** Biomarker changes (mitophagy and gene expression markers) appear within weeks, but functional improvements in strength and endurance in trials were measured over 2–4 months, so several weeks to a few months of consistent use should be expected before functional benefits, if any, emerge.

* **Common pitfalls:** A frequent mistake is assuming pomegranate juice or extract delivers Urolithin A directly — it does not, since the compound depends on individual gut bacteria for conversion. Another is expecting athletic performance gains in already well-trained individuals, where trials have shown little effect.

* **Regulatory status:** In the United States, Urolithin A is marketed as a dietary supplement and the branded ingredient has self-affirmed "generally recognized as safe" (GRAS) status; it is not an approved drug for any condition, so all use is non-prescription and outside formal regulatory efficacy review.

* **Cost and accessibility:** Urolithin A is relatively expensive compared with commodity supplements, and the most-studied branded products carry a premium; cost is a meaningful practical barrier for continuous long-term use.


## Interaction with Foundational Habits

* **Sleep:** The interaction with sleep is **largely indirect**. There is no established direct effect on sleep architecture, and the compound is not stimulating; an ongoing trial is specifically testing Urolithin A (combined with fisetin) for sleep and aging biomarkers, so a direct effect remains an open question rather than a demonstrated one.

* **Nutrition:** The interaction with nutrition is **direct and bidirectional**. Dietary ellagitannins (pomegranate, walnuts, berries) are the natural precursor, but conversion depends on gut bacteria; taking the supplement with a meal aids tolerability, and a fiber-rich diet supporting a healthy microbiome may favor native production in those who are producers.

* **Exercise:** The interaction with exercise is **potentiating and complementary**. Both exercise and Urolithin A promote mitochondrial quality and mitophagy, and the compound is positioned as a complement to — not a replacement for — resistance and aerobic training; benefits in trials were seen against a backdrop of normal activity, and experts commonly pair it with strength training and protein.

* **Stress management:** The interaction with stress management is **indirect with no established direct effect** on cortisol or the stress response. Any benefit is mechanistic and speculative, via reduced inflammation, rather than a demonstrated effect on stress physiology.


## Monitoring Protocol & Defining Success

Because Urolithin A is a well-tolerated supplement with no required clinical monitoring, formal lab surveillance is optional; the table below lists biomarkers that motivated individuals may track to gauge response, alongside qualitative markers. Baseline measurement before starting establishes a personal reference point.

Baseline testing should be performed before the first dose to capture starting values, and ongoing testing can be done at a relaxed cadence — for example at baseline, then every 3–6 months — given the absence of safety-driven monitoring requirements.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|----------------|
| High-sensitivity C-reactive protein (hs-CRP) | < 1.0 mg/L | Tracks the anti-inflammatory effect reported in trials | Fasting not required; avoid testing during acute illness, which transiently elevates it |
| Grip strength / leg strength | Higher is better; track personal trend | Functional readout of the muscle-strength benefit | Use the same device and protocol each time; best paired with a standardized endurance test |
| Muscle endurance (e.g., timed contractions or walk test) | Higher is better; track personal trend | Reflects the most consistent functional benefit seen in trials | 6-minute walk distance or a repeat-to-fatigue test; standardize time of day and footwear |
| Fasting metabolic panel (acylcarnitines/lipids if available) | Within optimal lab range | Secondary metabolic markers shifted in trials | Requires fasting; specialized acylcarnitine panels are not routinely available |

* Qualitative markers worth tracking are listed below.

* **Perceived energy and stamina:** day-to-day sense of physical endurance during activity.

* **Exercise recovery:** subjective recovery and reduced fatigue after training sessions.

* **Muscle function in daily tasks:** ease of stairs, carrying, and standing from seated.

* **General well-being:** overall vitality, which may reflect reduced inflammation.


## Emerging Research

* **Immune aging trial (completed):** A placebo-controlled study tested Urolithin A's effect on age-related immune decline, reporting shifts toward a more youthful immune profile in midlife adults; see [Denk et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41174221/) and registry entry [NCT05735886](https://clinicaltrials.gov/study/NCT05735886) (50 participants, immune and mitochondrial endpoints in T-cells).

* **Cognition and brain longevity (active):** A large trial ([NCT07060898](https://clinicaltrials.gov/study/NCT07060898), 650 participants) is evaluating a Urolithin A-containing supplement on cognitive function and related outcomes in aging adults, a direction that could strengthen the case if positive.

* **Muscle strength confirmation (recruiting):** [NCT07231783](https://clinicaltrials.gov/study/NCT07231783) (120 participants) is testing Urolithin A on isokinetic knee strength in healthy middle-aged adults, directly probing whether the earlier strength signal replicates in a larger sample.

* **Sleep and aging biomarkers (recruiting):** [NCT06990256](https://clinicaltrials.gov/study/NCT06990256) (80 participants) is examining Urolithin A combined with fisetin on sleep quality and aging biomarkers, extending the compound into a new domain.

* **Cancer and immunotherapy (recruiting):** Trials including [NCT07161310](https://clinicaltrials.gov/study/NCT07161310) (solid tumors with checkpoint inhibitors) and the prostate-cancer [URO-PRO trial, NCT06022822](https://clinicaltrials.gov/study/NCT06022822) (90 participants, Phase 2) are studying Urolithin A in oncology; these could either reveal new benefits or, conversely, surface effects that complicate use in people with cancer.

* **Athletic performance limits:** A trial in highly trained distance runners ([Whitfield et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40839339/)) examined running performance and recovery, contributing evidence on where Urolithin A does and does not help and tempering claims of universal performance benefit.

* **Future research directions:** Key open questions — longer-duration safety and efficacy, whether biomarker changes translate into hard clinical outcomes, and whether benefits extend reliably beyond muscle to immune, cognitive, and cardiovascular endpoints — are flagged by the systematic review of [Kuerec et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39002645/), which explicitly calls for studies across more physiological systems and longer intervention periods.


## Conclusion

Urolithin A is a compound made by gut bacteria from substances in pomegranates, walnuts, and berries, and is available as a supplement because many people cannot produce useful amounts on their own. Its appeal rests on a clear idea: helping cells clear out worn-out energy-producing parts, a process that fades with age. In human trials, the most consistent benefits have been modest gains in muscle strength and endurance in middle-aged and older adults, along with small reductions in inflammation markers. Newer work points toward possible benefits for immune cell health, while effects on aerobic fitness have been mixed and benefits in already-fit people appear limited.

The evidence is encouraging but still early. Trials have been short — generally a few months — so the long-term value and safety for a lifelong longevity goal remain unproven, and several results come from studies tied to the product's developer, which is worth keeping in mind. Short-term safety looks reassuring, with side effects no greater than placebo. For someone focused on healthy aging, Urolithin A is a reasonably well-tolerated option with a plausible mechanism and real but modest measured benefits, set against meaningful gaps in the long-term and broader-outcome evidence that currently remains absent.


**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**


<section id="iterations" markdown="1"></section>